News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
ChartMill Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Sprott Inc. and its subsidiary Sprott Asset Management USA Inc. have reported beneficial ownership of 37,776,350 common shares of i-80 Gold Corp. (IAUX), representing a 5.3% stake. Both entities hold shared voting and shared dispositive power over these shares, which are directly owned by …
Protagonist Therapeutics (PTGX) stock reached an all-time high of $155.01, just shy of its 52-week high, with a market capitalization of $10 billion, representing a 175.66% increase over the past year. This surge is attributed to growing investor confidence and positive developments in its …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Sprott stock has delivered a very strong multi year return, yet the current valuation …
Sharemaestro market context Price below Trend Line 52 weeks +81.1%Dimensional Fund Advisors LP significantly increased its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 133.9% in the first quarter, now holding over 531,000 shares valued at $2.77 million. Other institutional investors have also adjusted their holdings, with hedge funds and institutions collectively owning 38.13% …
Farallon Capital Management, L.L.C. has disclosed a significant stake in Protagonist Therapeutics (PTGX), reporting beneficial ownership of 6,433,119 shares, which represents 9.99% of the company's outstanding common stock. This ownership includes 6,348,906 direct shares and 1,500,000 common stock purchase warrants, although the warrants are …
Janus Henderson Group Ltd. has disclosed an 8.4% passive ownership stake in Protara Therapeutics, Inc. (TARA) through its asset managers, holding 4,696,709 shares of common stock. These shares are managed on behalf of client accounts, referred to as Managed Portfolios, with Janus Henderson exercising …
Sprott Inc. (TSE:SII) is set to trade ex-dividend soon, with a dividend payment of US$0.40 per share scheduled for September 1st. The company boasts a comfortable payout ratio of 39% of its profit, indicating a sustainable dividend, and has shown strong earnings growth of …
Sharemaestro market context Price below Trend Line 52 weeks +81.1%Quantinno Capital Management LP significantly increased its stake in Proto Labs, Inc. (NYSE:PRLB) by 98.9% in the first quarter, now owning 27,716 shares valued at $1.58 million. This comes as Proto Labs reported strong quarterly earnings, beating analyst estimates with an EPS of $0.60 …
Protagonist Therapeutics (NASDAQ:PTGX) has received an average "Moderate Buy" rating from eighteen brokerages, with an average 12-month price target of $137.86. The company recently reported strong quarterly earnings and revenue, exceeding consensus estimates, while its shares trade near their 12-month high. Despite recent insider …
Protagonist Therapeutics CEO Dinesh Patel sold 100,000 shares of the company's common stock for approximately $14.9 million on August 10 and 11, 2026. These sales were part of a pre-arranged 10b5-1 trading plan after exercising stock options at $21.58 per share. The transactions occurred …
Protagonist Therapeutics President and CEO Dinesh V. Patel exercised stock options for 100,000 shares at $21.58 each and subsequently sold all 100,000 shares in open-market transactions on August 10-11, 2026. The sales, conducted under a Rule 10b5-1 trading plan, generated approximately $14.89 million in …
Protagonist Therapeutics CEO Dinesh Ph. Patel sold 34,239 shares of company stock for over $5 million on August 11th, reducing his stake by 6.14% while still holding a significant position. This transaction, made under a pre-arranged trading plan, occurred as PTGX shares rose 2.5% …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 10 a.m. ET CALL PARTICIPANTS CFO and Co-COO - Kevin Hibbert CEO of Sprott Asset Management - John Ciampaglia Mr. - Whitney George Full Conference Call Transcript Operator: Good morning, ladies and gentlemen, …
Sharemaestro market context Price below Trend Line 52 weeks +81.1%Proto Labs (PRLB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The …
Sharemaestro market context Trend signal active 52 weeks +81.2%H.C. Wainwright has reiterated its Buy rating for Protara Therapeutics (TARA.US), maintaining a target price of $27. This decision reflects the firm's continued positive outlook on the company's prospects.
This article from Stock Traders Daily provides a detailed AI-driven analysis of Prothena Corporation Plc (PRTA), highlighting strong near-term sentiment but a neutral mid and long-term outlook. It outlines specific institutional trading strategies (Long, Momentum Breakout, and Risk Hedging) with entry/target/stop-loss zones, and presents …
Proto Labs Inc. (PRLB) shares have reached a new 52-week high of $92.00, driven by an impressive 90% total return over the past year and nearly 79% year-to-date. This growth follows strong Q2 results, exceeding analyst expectations with record revenue and adjusted earnings, and …
Protagonist Therapeutics has received FDA approval for ICOTYDE to treat moderate-to-severe plaque psoriasis, reinforcing its "Strong Buy" rating. The company is also advancing rusfertide for polycythemia vera, with an FDA Priority Review decision expected by August 2026, and developing PN-881 for psoriasis. These developments …
Search by ticker symbol or company name and select a result to open its chart.